2008 Annual Progress Report

Total Page:16

File Type:pdf, Size:1020Kb

2008 Annual Progress Report International AIDS Vaccine Initiative 2008 Annual Progress Report avi IAVI’s mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. OFFICES New York Headquarters 110 William Street, Floor 27 New York, N..Y. 10038-3901 U.S.A. Tel: +1 212 847 1111 Fax: +1 212 847 1112 East Africa Postal address: P.O. Box 340 KNH Nairobi, Kenya 00202 Tel: +254 20 445 3596/7 Fax: + 254 20 445 3598 Europe Herengracht 208 1016 BS Amsterdam The Netherlands Tel: +31 20 521 0030 Fax: +31 20 521 0039 India D-64, Second Floor, Defence Colony New Delhi, 110 024, India Tel: +91 11 24652668 Fax: +91 11 24646464 Southern Africa Ground Floor, Block 6, Albury Park Corner Albury Road & Jan Smuts Avenue Dunkeld West 2196 Johannesburg, South Africa Tel: +27 11 325 4737 Fax: +27 11 759 6210 www.iavi.org ) [email protected] Copyright © 2009 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative, IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc. This report is available online at http://www.iavi.org. Evolution The new AIDS Vaccine The new IAVI Neutralizing A fully operational Design and Development Antibody Center at The Innovation Fund to promote Laboratory Scripps Research Institute cutting-edge science JULIANA THOMAS PHOTOGRAPHY Commitment Global Clinical Community network of trial center outreach and partnerships support social science VANESSA VICK Promise Build scientific and Sustain local, Ensure access to human capacity in national and global vaccines where the developing world focus on ending AIDS they’re needed most VANESSA VICK Message from the President Since we were founded in 1996, the International AIDS Vaccine Initiative has undergone constant change as we have pursued our mission of ensuring the development of an AIDS vaccine for the world. Still, 2008 stands out as a particularly eventful period in our history. As part of our ongoing efforts to address the scientific challenges facing AIDS vaccine designers, IAVI in 2008 significantly expanded our applied research program, aimed at informing the design of improved AIDS vaccine candidates. We opened a new laboratory in New York City and a joint facility with The Scripps Research Institute in California. With the benefit of IAVI-supported clinical research centers in Africa, we stepped up the search for HIV-infected individuals who produce neutralizing antibodies to HIV. And we fully operationalized our Innovation Fund, which finances out-of-the box technologies that could advance AIDS vaccine research and development. Together, these efforts at year’s end produced an advance that may help accelerate the solution of the key problem of how to design a vaccine that elicits neutralizing antibodies to HIV. But that’s just part of our 2008 story, of course. The full picture is provided in the following report. IAVI is called an “initiative” for a reason—those of us who work at IAVI are only a part of the endeavor. None of what we achieved last year, or in any of IAVI’s history, would have been possible without the commitment of our many partners and collaborators, including political leaders, policy makers, scientists, members of civil society and multilateral groups. We are continually enlightened by our engagement with partners, and grateful for their generosity. We are especially indebted to the volunteers who graciously participate in clinical trials and studies. They are the greatest heroes of AIDS vaccine R&D. And last but not least, we also are grateful to our many generous donors, whose sustained support for us despite the challenging economic environment is a source of great inspiration. We thank those of you who have been a part of our mission, and invite the rest of you to join us as we continue to move toward our vision of a world without AIDS. 6 International AIDS Vaccine Initiative INTRODUCTION HOPE AMID CRISIS She arrived tired and weak, but with a hope that had steeled her through the long trip to Entebbe. Her name was Rose, and she presented two granddaughters no older than 10, colorfully outfitted in matching ruffled dresses. Wiping the perspiration from her brow with a handkerchief, Rose explained to the staffer at the International AIDS Vaccine Initiative’s Uganda office that she already had lost the girls’ mothers and two additional children to AIDS, and now she was raising seven grandchildren left behind. At that moment, more than 1.5 million Ugandans had died of AIDS, leaving behind more than 1 million orphans. Rose had taken that long trip on a very hot day, having read in the newspaper that “the vaccine people” had arrived in Uganda. Now she wanted to get her granddaughters an inoculation that would protect them from the fate of their lost mothers. Rose imagined a world without AIDS, but she was In this report too early. The IAVI staffer explained the purpose of the 8 | Overview organization’s presence in Uganda: to test experimental AIDS vaccines in an effort to one day develop an effective vaccine. 12 | Research & Development She gave Rose and her granddaughters tea and cookies, the best information available on how to prevent HIV infection and a 22 | Working referral to an HIV-prevention education group in Kampala. with Communities Rose’s story, and those of millions of others like Rose, her 25 | Sustaining Support daughters and her grandchildren, motivate the work we do at IAVI. Individuals like Rose have lost too much. Young people 29 | Looking Ahead like her grandchildren are in far too grave a danger. We need to be able to offer them more than tea and the same prevention 31 | Financial Abstract advice that has the world registering 7,400 new HIV infections 32 | About IAVI every single day. We need to offer a revolutionary change. At IAVI, we believe the development of an AIDS vaccine 35 | Summary of can be that revolutionary change. This report describes 2008 Achievements our progress in 2008 toward our mission of ensuring the development of a safe, effective, accessible, preventive AIDS vaccine for use throughout the world. Such a vaccine offers the best hope of ending the AIDS pandemic and returning us to a world without AIDS. 2008 Annual Progress Report 7 PART I OVERVIEW Meeting the challenge 2008 was a year of considerable transition for IAVI. Most notably, it was the year the organization added its own bricks-and-mortar dimension to an expanding, global applied research program, opening two state-of-the-art facilities. IAVI’s applied research program is aimed at AIDS Vaccine Primer expediting the solution of the scientific problems that so far IAVI’s ultimate goal is a vaccine that have stymied the design of effective AIDS vaccine candidates. prevents the establishment of persistent HIV infection and is applicable for use in the regions of the world hit hardest IAVI was not originally created to address problems of by the AIDS epidemic. An intermediate complex science. IAVI was conceived in 1996 as a group that goal could be a vaccine that does not prevent infection but that controls HIV would advocate for the development of an accessible AIDS replication and thus delays the onset vaccine, explore public policy reforms that would promote of AIDS by reducing the amount of the virus present in the body. Unfortunately, AIDS vaccine research and development, and develop and test the very nature of HIV presents daunting AIDS vaccine candidates. But over time, as scientists learned challenges that transcend traditional research and development models: more about HIV and its interactions with the immune system, it became clear that conventional vaccinology would not Rapid mutation produce a fully protective AIDS vaccine. Rather, researchers Once established in the body, HIV copies itself quickly. With each copy, genetic would need to unlock some of the mysteries of HIV and the mistakes occur, resulting in a huge body’s response to the virus to design novel vaccine concepts number of viruses with slightly different compositions. An effective vaccine would that would go beyond the initial approaches. have to target the many different types of HIV circulating in the world. After a 2001 IAVI-commissioned survey of global efforts Camouflage to design AIDS vaccine candidates pointed to gaps in the HIV is stealthy, able to hide itself in host cells, spread quickly and build reservoirs field, IAVI began investing not just in product development of infection. of candidates but in the design of novel ones to help fill the identified gaps. These investments led to the establishment The target HIV attacks and quickly impairs the of scientific consortia to tackle the major challenges and body’s immune system, killing the very culminated in the opening in 2008 of a new 36,000-square- cells that orchestrate responses to pathogens. This leaves the infected foot facility in New York City to house IAVI’s AIDS Vaccine person vulnerable to other contagions as Design and Development Laboratory, which had been well, and AIDS sets in. incubated at the State University of New York’s Downstate No ideal animal model Medical Center in Brooklyn. The Design Lab is an industry- HIV causes AIDS only in humans. To learn from animal models, researchers style facility devoted to developing a new generation of more must study a similar virus (simian effective AIDS vaccine candidates, and to prioritizing vaccine immunodeficiency virus or SIV) or a hybrid candidates to ensure that the most promising are accelerated (SHIV) in non-human primates. This is an immense aid, but the differences between to clinical testing. These efforts complement the vaccine HIV on the one hand and SIV or SHIV design and development work IAVI is undertaking with on the other, coupled with the genetic and immunologic differences between partners around the world.
Recommended publications
  • Vaccine Hesitancy
    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
    [Show full text]
  • Clinical Scholars Visit Amish Research Clinic in Lancaster County, PA by Patrick Brunner, MD Dr
    Spring 2018 Center for Clinical and Translational Science e- e-NewsletterNewsletter Center News James Krueger and Marina Caskey, Representing the Nussenzweig Lab Team, Honored at Translational Science 2018 Meeting By Hospital Leadership which fulfill the translation research Dr. James Krueger received paradigm of going from bench to the Association for Clinical and bedside, have been recognized by this Translational Science (ACTS) most prestigious national recognition. Distinguished Investigator Award for his It is well deserved!” Upon receiving the groundbreaking research on psoriasis at award, Dr. Krueger noted, “This award the Translational Science 2018 meeting would not have been possible without attended by more than 1,100 people in the support of many others associated Washington, DC in April. His research with the Rockefeller CTSA enterprise: has led to a fundamental change in my lab members, the nursing staff, the paradigm for understanding the all other support departments and, pathophysiology of the disorder, and of course, hundreds of patients who this in turn has led to the development directly tested progressively better drugs of a series of novel medications that that are now used to so effectively treat precisely modulate the immune system psoriasis.” and dramatically improve the therapy of the disorder. Each year, Clinical Research Forum sponsors a competition to identify Dr. Caskey Receiving “Top Ten” Award from the “Top Ten” Clinical Research Drs. Harry Selker and Herb Pardes studies reported in the previous year. commented that “The study reflects the The competition is intense and so it very best in translational science: the is a true tribute to the novelty and careful analysis of patient phenotypes; importance of the study led by Dr.
    [Show full text]
  • Report on Global Surveillance of Epidemic-Prone Infectious Diseases, 2000
    Pan American Health Organization Regional Office of the World Health Organization PAHO/DPC/CD-V/243/03 Original: English Report: Workshop on Dengue Burden Studies (Washington, DC, 5-7 November 2002) Convened by The Pan American Health Organization The Rockefeller Foundation The Pediatric Dengue Vaccine Initiative Executive Summary Background Dengue fever (DF) and dengue hemorrhagic fever (DHF) are caused by the mosquito borne virus, dengue virus, of which there are four antigenically distinct serotypes. It is estimated that annually these viruses cause at least 20 million infections worldwide leading to some 24,000 deaths (WHO, http://www.who.int/health_topics/dengue/en/ ). The alarming rise in dengue hemorrhagic fever in the world today is illustrated most starkly by the chart below which represents data from the World Health Organization (WHO) showing the rise of DHF cases over the last four decades. Indeed the first two years of the new millennium has seen outbreak after outbreak of DHF not only in Southeast Asia where DHF has been seen for half a century, but also in many countries of South and Central America. REPORTED CASES OF DHF 600 ds 500 housan t 400 n d i e 300 200 r report e 100 numb 0 1955-1959 1960-1069 1970-1979 1980-1989 1990-1998 Source: WHO; adapted from http://www.who.int/health_topics/dengue/en/ While there is no doubt that severe dengue is spreading from countries in Southeast Asia to countries in the Pacific and in the Americas, there is also no doubt that many international efforts into the development of dengue vaccines have led to a number of promising vaccine candidates which may offer some solutions to the control of this disease.
    [Show full text]
  • V21 MTG 0033 List of Particip
    THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici
    [Show full text]
  • 5Th Annual Short Course in Medical Virology Baltimore, MD August 5-11
    5th Annual Short Course in Medical Virology Baltimore, MD ǀ August 5-11, 2018 ǀ Program Locations: IHV ǀ Baltimore JH ǀ Baltimore NIH ǀ Bethesda Sunday, August 5 3:00 PM Hotel Check In 6:00-8:00 PM Short Course Opening Dinner at Diamond Tavern Monday, August 6 9:00-10:00 AM Shyam Kottilil, MD, PhD, Institute of Human Virology "Hepatitis C" 10:00-10:15 AM Coffee break 10:15- 11:15 AM Yutaka Tagaya, MD, PhD, Institute of Human Virology "Human T-cell leukemia virus-1, an exceptionally oncogenic retrovirus" 11:15-12:15 PM Robert Gallo, MD, Institute of Human Virology "Human Retroviruses: HTLV and HIV: an Overview” 12:15- 1:15 PM group picture & lunch 1:15-2:15 PM Jose Esparza, MD, PhD, Institute of Human Virology "Vaccines" 2:15-3:15 PM Alfredo Garzino-Demo, PhD, Institute of Human Virology "HIV Pathogenesis" 3:15-3:30 PM Coffee break 3:30- 4:30 PM Neil Constantine, PhD, Insitute of Human Virology "Laboratory diagnostics" Tuesday, August 7 8:15 AM Transportation to Johns Hopkins Bloomberg School of Public Health 9:00-10:00 AM Diane Griffin, PhD, MD, Johns Hopkins Bloomberg School of Public Health "Measles" 10:00-11:00 AM Ken Olson, PhD, Colorado State University "Arboviruses" 11:00-11:30 AM Break 11:30-12:30 AM Marcelo Jacobs-Lorena, PhD, Johns Hopkins Bloomberg School of Public Health Insectary Tour 12:30-1:30 PM Lunch 1:30-2:30 PM Transportation to IHV/ Coffee Break 2:30-4:30 PM GVN Short Course Partcipant's research presentations 4:30-5:30 PM Yuki Furuse, PhD, MD, Tohoku University, Japan New Emerging leader presentation: What can we do and what should we do during Ebola outbreak? Wednesday, August 8 9:00-10:00 AM Ab Osterhaus, DVM, PhD, University of Veterninary Medicine Hannover "One Health" 10:00-11:00 AM Stefan Sarafianos, PhD, Emory School of Medicine "Antiviral drug discovery" 11:30- 12:30 AM Robert Garry, PhD, Tulane University "Ebola and Lassa fever" 12:30-1:30 PM Lunch 1:30-2:30PM Konstantin Chumakov, FDA “Polio and other Enteroviruses” 2:30-3:30 PM Richard H.
    [Show full text]
  • José Esparza MD, Phd - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
    Vaccination: lost opportunities José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. - Formerly at the World Health Organization (Geneva, Switzerland) and the Bill & Melinda Gates Foundation (Seattle, WA, USA). Outline • The public health value of vaccination • Different types of vaccine hesitancy • Some historical examples of vaccine introduction and impact • The case of dengue vaccines • Conclusions Ten Great Public Health Achievements of the 20th Century (in the US) 1. Vaccines 2. Motor vehicle safety 3. Workplace safety 4. Control of infectious diseases 5. Decline in deaths from hearth disease and stroke 6. Safer and healthier foods 7. Healthier mothers and babies 8. Family planning 9. Fluoridation of drinking water 10. Tobacco as a health hazard www.cdc.gov/about/history/tengpha.htm The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) Vaccine-preventable diseases, by year of vaccine development or licensure. United States,1798-1998. Vaccine Introduction Vaccine Introduction Smallpox 1798 Rubella 1969 Rabies 1885 Antrax 1970 Typhoid 1896 Meningitis 1975 Cholera 1896 Pneumonia 1977 Plague 1897 Adenovirus 1980 Diphtheria 1923 Hepatitis B 1981 Pertussis 1926 H. Influenza B 1985 Tetanus 1927 Japanese encephalitis 1992 Tuberculosis 1927 Hepatitis A 1995
    [Show full text]
  • Piecing Together the HIV Prevention Puzzle AVAC Report 2009 Acknowledgments
    Piecing Together the HIV Prevention Puzzle AVAC Report 2009 Acknowledgments AVAC gratefully acknowledges many friends and colleagues in government, industry, academia and the advocacy community from all over the world for their expertise, guidance and advice as we researched and prepared this Report. AVAC Report 2009 was written and edited by AVAC staff, consultants and board members, and coordinated by Emily Bass. We also want to especially thank Sarah Alexander, Dan Barouch, Linda-Gail Bekker, Seth Berkley, Alan Bernstein, Susan Buchbinder, Gabriela Calazans, Ward Cates, Mark Connors, Larry Corey, Paul de Bakker, Guy de Bruyn, Kevin De Cock, Carl Dieffenbach, Kim Dickson, Jose Esparza, Tim Farley, Patricia Fast, Mark Feinberg, Jorge Flores, David Goldstein, Gregg Gonsalves, Glenda Gray, Yasmin Halima, Cate Hankins, Mark Harrington, Barton Haynes, Sharon Hillier, Peggy Johnston, Richard Klausner, Wayne Koff, Katharine Kripke, Jim Kublin, Dave Levin, Udom Likhitwonnawut, Margaret Liu, Ying Ru Lo, Donna Lomangino, Siobhan Malone, Kay Marshall, Betsy Martin, John Mascola, Bonnie Mathieson, Margaret McCluskey, Elizabeth McGrory, James McIntyre, Natasha Mileshina, Lynn Morris, Kevin O’Reilly, Saladin Osmanov, Myra Ozaeta, Giuseppe Pantaleo, Lynn Paxton, Louis Picker, Frances Priddy, Helen Rees, Robert Reinhard, Supachai Rerks-Ngarm, Mike Robertson, Candace Rosen, Nina Russell, Jerry Sadoff, Jeff Safrit, Allan Schultz, Robin Shattock, Guido Silvestri, Joan Tallada, Jim Tartaglia, Gerald Voss, Sabrina Welsh and Carolyn Williamson. AVAC is dedicated
    [Show full text]
  • Vol. 23, No. 2, 2019
    The Publication on AIDS Vaccine Research WWW.IAVIREPORT.ORG | VOLUME 23, ISSUE 2 | DECEMBER 2019 A new viral vaccine The history of A new efficacy trial of vector has broad vaccination: adapting the mosaic HIV vaccine potential to the times candidate FROM THE EDITOR “It was the best of times, it was the worst of times…” from Janssen Vaccines & Prevention, part of the Jans- So begins Charles Dickens’s famous historical novel A sen Pharmaceutical Companies of Johnson & Johnson, Tale of Two Cities, published in 1859. Dickens was together with a consortium of public partners, began describing the years leading up to the French their second, and largest, efficacy study (named Revolution, yet it is an oddly apt description of the Mosaico) of Janssen’s mosaic-based HIV vaccine candi- current state of the vaccine field. date (see page 16). This October, the first Ebola vaccine was approved by Based on this, one might think it was the best of times. the European Medicines Agency. This is by all accounts But amidst all this progress, global cases of measles are an important milestone in battling outbreaks of a lethal on the rise, a disease for which a highly effective vaccine infectious disease that most often affects people in devel- has been available for more than 50 years. Last year oping countries. This vaccine, known as Ervebo, was more than 140,000 people worldwide died of measles, rapidly developed in 2014 during the deadliest outbreak most of them children under five years old, and 100 mil- of Ebola in history. It is estimated to be 97.5% effective.
    [Show full text]
  • Emerging and Reemerging <Italic>Aedes</Italic>-Transmitted Arbovirus Infections in the Region of the Americas: Impli
    AJPH PERSPECTIVES Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy The increasing geographical spread Marcos A. Espinal, MD, DrPH, Jon K. Andrus, MD, Barbara Jauregui, MD, MSc, Stephen Hull Waterman, and disease incidence of arboviral MD, MPH, David Michael Morens, MD, Jose Ignacio Santos, MD, MSc, Olaf Horstick, PhD (DrMed), FFPH, infections are among the greatest MPH, MSc, MBBS, Lorraine Ayana Francis, DrPH, MHA, and Daniel Olson, MD public health concerns in the Americas. The region has observed — an increasing trend in dengue in- he ever-increasing geo- symptomatic infections way ZIKV, like CHIKV, had not Tgraphical spread and rising above the numbers reported to previously circulated within cidence in the last decades, evolv- disease incidence of arboviral PAHO.9 the Western Hemisphere, and ing from low to hyperendemicity. (arthropod-borne virus) in- In 2005, CHIKV caused an resulted in an explosive outbreak Yellow fever incidence has also in- fections are among the most outbreak on the island of in the Americas, with its identi- tensified in this period, expanding significant public health concerns Comoros, followed by a large fication first on Easter Island, from sylvatic-restricted activity in the Americas.1,2 In addition to outbreak in India, resulting in Chile, in 2014, followed by to urban outbreaks. Chikungunya the reemergence of dengue virus more than 1 million cases and northeast Brazil in 2015, and started spreading pandemically in (DENV) and yellow fever virus significant postinfectious mus- then spreading throughout the 2005 at an unprecedented pace, (YFV), new arboviral pathogens culoskeletal sequelae.
    [Show full text]
  • 5Th Annual Course in Medical Virology of the Global Virus Networkǀ Baltimore, MD, August 5-11, 2018 Draft Program
    5th Annual Course in Medical Virology of the Global Virus Networkǀ Baltimore, MD, August 5-11, 2018 Draft Program Locations: IHV/Baltimore JH/Baltimore NIH/Bethesda Day Time Activity Sunday, August 5 3:00 PM Hotel Check In 6:00-8:00 PM Short Course Opening Dinner Monday, August 6 9:00-10:00 AM Shyam Kottilil, MD, PhD, Institute of Human Virology "Hepatitis C" 10:00-10:15 AM Coffee break 10:15- 11:15 AM Yutaka Tagaya, MD, PhD, Institute of Human Virology "Human T-cell leukemia virus-1, an exceptionally oncogenic retrovirus" 11:15-12:15 PM Robert Gallo, MD, Institute of Human Virology "Human Retroviruses: HTLV and HIV: an Overview” 12:15- 1:15 PM Lunch 1:15-2:15 PM Patrick Ryscavage, MD, Center for Infectious Diseases "The Jacques Initiative: A Community-Oriented Approach to the Baltimore HIV Epidemic" 2:15-3:15 PM Man E. Charurat PhD, MHS, Institute of Human Virology "Biosurveillance" 3:15-3:30 PM Coffee break 4:00- 5:00 PM Neil Constantine, PhD, Insitute of Human Virology "Laboratory diagnostics" Tuesday, August 7 8:15 AM Transportation to Johns Hopkins Bloomberg School of Public Health 9:00-10:00 AM Diane Griffin, PhD, MD, Johns Hopkins Bloomberg School of Public Health "Measles" 10:00-11:00 AM TBA "Arboviruses" 11:00-11:30 AM Break 11:30-12:30 AM Insectary Tour 12:30-1:30 PM Lunch 1:30-2:30 PM Transportation to IHV/ Coffee Break 2:30-3:30 PM GVN Short Course Partcipant's research presentations- Part 1 3:30-4:30 PM TBA New Emerging leader presentation Wednesday, August 8 9:00-10:00 AM Ab Osterhaus, DVM, PhD, University of Veterninary Medicine Hannover "One Health" 10:00-11:00 AM Christian Bréchot, MD, PhD, Global Virus Network "Hepatitis B and HCC" 11:30- 12:30 AM Robert Garry, PhD, Tulane University "Ebola" 12:30-1:30 PM Lunch 1:30-2:30PM Konstantin Chumakov, FDA “Polio and other Enteroviruses” 2:30-3:30 PM TBA Bioinformatics 3:30-3:15 PM Coffee Break 3:15-4:15 PM Kathleen M.
    [Show full text]
  • Human Virology in Latin America Juan Ernesto Ludert • Flor H
    Human Virology in Latin America Juan Ernesto Ludert • Flor H. Pujol Juan Arbiza Editors Human Virology in Latin America From Biology to Control Editors Juan Ernesto Ludert Flor H. Pujol Instituto Politécnico Nacional Centro de Microbiologia y Biologia Celular Center for Research and Advances Studies Instituto Venezolano de Investigaciones Mexico City, Mexico Científicas (IVIC) Caracas, Venezuela Juan Arbiza Facultad de Ciencias Universidad de la Republica Montevideo, Uruguay ISBN 978-3-319-54566-0 ISBN 978-3-319-54567-7 (eBook) DOI 10.1007/978-3-319-54567-7 Library of Congress Control Number: 2017937370 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Global Vaccine and Immunization Research Forum (GVIRF) 15 to 17 March 2016 Hilton Sandton Hotel, Johannesburg, South Africa
    Global Vaccine and Immunization Research Forum (GVIRF) 15 to 17 March 2016 Hilton Sandton Hotel, Johannesburg, South Africa PROVISIONAL LIST OF PARTICIPANTS Scientific Organizing Committee Dr Jean-Pierre Amorij, Chief Technology Officer & Founder, Virtuvax, Abcoude, Netherlands Dr Norman W. Baylor, President and Chief Executive Officer, Biologics Consulting Group, Inc., Alexandria, VA, USA Professor David Durrheim, Director of Health Protection, Hunter New England Area Health Service and Professor of Public Health, University of Newcastle, Eleebana, Australia Dr Thomas G. Evans, President and Chief Executive Officer, Aeras, Rockville, MD, USA (Unable to attend) Dr Ingileif Jonsdottir, Professor of Immunology, Department of Immunology, Landspitali, The University Hospital of Iceland, Reykjavik, Iceland (Unable to attend) Professor Gagandeep Kang, Professor and Head, The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Tamil Nadu, Vellore, India (Unable to attend) Dr Rosanna Lagos, Coordinadora, Centro para vacunas en Desarollo-Chile, Hospital de Niños Roberto del Rio, Santiago, Chile (Unable to attend) Dr Odile Leroy, Executive Director, European Vaccine Initiative, Heidelberg, Germany Dr Kathleen Neuzil, Director, School of Medicine, University of Maryland, Center for Vaccine Development, Baltimore, Maryland , USA Dr Bernhards Ragama, Chief Research Officer, Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya Dr Alexander R Precioso, Director, Clinical Trials
    [Show full text]